+A -A

Tabela:
Comparative View:

1Q17 Create chart
Net sales revenues 951,989
Change in Fair Value of Biological Assets 42,721
Cost of Goods Sold -629,377
Depreciation / Amortization / exhaustion -99,163
Exhaustion of biological assets -34,078
Gross Profit 232,092
Selling Expenses -146,751
General and Administrative Expenses -34,736
Management Compensation -3,790
Other Operating Compensation 2,992
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 49,807
Financial Income 41,670
Financial Expenses -104,504
Income Before Income Tax and Social Contribution -13,027
Income and social contribution taxes - current -17,567
Income Tax and Social Contribution - Deferred 23,080
Effect profit from discontinued operation 0
Net Income -7,514
Recurring Net Income -9,278
Recurring EBITDA 148,171
EBITDA Margin 15.6 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza